Added Value of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Predicting Response to Somatostatin Analogs in Acromegaly Patients.
Journal
Turkish neurosurgery
ISSN: 2651-5032
Titre abrégé: Turk Neurosurg
Pays: Turkey
ID NLM: 9423821
Informations de publication
Date de publication:
2019
2019
Historique:
pubmed:
23
3
2019
medline:
18
2
2020
entrez:
23
3
2019
Statut:
ppublish
Résumé
To investigate the added value of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) sequences in predicting somatostatin analog (SSA) responses in patients with acromegaly. This study included 55 active acromegaly patients with macroadenoma. Mean and maximum signal intensities were measured using region of interests in T2-weighted (T2W) and DCE-MRI sequences. Semi-quantitative values indicating relative signal intensity ratios and contrast-enhanced kinetics were obtained. Bivariate and multivariate analyses were used to determine whether the pathological granulation pattern of adenomas (dense versus others) was associated with patients' demographic variables and semi-quantitative MRI parameters. Three parameters formed the logistic model, x2(3)=23.278, p < 0.0001: age (odds ratio [OR]=1.08), hypointensity of adenomas in T2W images (OR=15.45), and high maximum enhancement ratio in the second interval (ER2max) values (OR=2195.74). The overall accuracy of this model was 85.45% with an area under the curve of 0.880. Sensitivity, specificity, positive predictive, and negative predictive values of the model were 68.75%, 92.31%, 78.58%, and 87.8%, respectively. In patients with newly diagnosed acromegaly, the model created based on the relative T2W signal intensity, patient's age, and ER2 < submax parameter from DCE-MRI sequences might be used to more accurately predict SSA responses.
Identifiants
pubmed: 30900736
doi: 10.5137/1019-5149.JTN.26003-19.1
doi:
Substances chimiques
Contrast Media
0
Human Growth Hormone
12629-01-5
Somatostatin
51110-01-1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM